Find a Clinical Trial by Adult Cancer Type

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

Back to Adult Cancers

Cancer Type: Breast

47 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Show: Only Breast specific trials All trials that include Breast

Doctor	Protocol No.	Title
Asher, Arash	A011401	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (IRB#45777)
Balmanoukian, Ani	M15-862	M15-862: A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects with Advanced Solid Tumors (IRB#46931)
Balmanoukian, Ani	GO39733	GO39733 : A phase IA/IB open-label, dose-escalation study of the safety and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic tumors (IRB#49235)
Basho, Reva	SGNLVA-002	SGNLVA 002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (IRB#52102)
Boasberg, Peter D	4020-01-001	4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (IRB#49142)
Chung, Alice	IIT2018-28-CHUNG-VR4BR	VR 4 BR: Effects of Virtual Reality on Women Undergoing Mastectomy with Breast Reconstruction - A Pilot Study (IRB#55330)
Chung, Alice	IIT2015-06-CHUNG-SNBO	Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65 (IRB#41396)
Freedland, Stephen	IIT2018-19-GRESH-DIGISTEP	Digitally-captured Step counts for Evaluating Performance Status in Advanced Cancer Patients: A single cohort, prospective trial (Digi-STEPS) (IRB#55271)
Gayther, Simon	1080	The Gilda Radner Hereditary Cancer Program (IRB#1080)
Giuliano, Armando	AFT-25	AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial (IRB#48166)
Gutierrez, Rodolfo	AB928CSP0005	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies (IRB#55460)
Hamid, Omid	INCAGN2385-101	A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies (IRB#53179)
Hamid, Omid	INCAGN1876-101	A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors (IRB#43777)
Hamid, Omid	INCAGN2390-101	INCAGN2390-101: A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies (IRB#54179)
Hamid, Omid	NC318-01	NC318-01: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (IRB#54833)
Hamid, Omid	R3767-ONC-1613	R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031)
Hamid, Omid	INCAGN1876-201	INCAGN 1876-201: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (IRB#47508)
Hamid, Omid	CTMX-M-072-001	An open-label, dose-finding and proof of concept study of the PD-L1 probody therapeutic, CX-072, as monotherapy and in combination with yervoy (ipilimumab) or with zelboraf (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas (IRB#46401)
Hamid, Omid	587-00	587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410)
Hamid, Omid	CMIW815X2102J	CMIW815X2102J: A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas (IRB#49591)
Kamrava, Mitchell	NRG-BR002	NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (IRB#51520)
Klempner, Samuel	TAPUR	Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119)
Klempner, Samuel	M16-438	M16-438: A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands (IRB#49976)
Limvorasak, Suwicha	IIT2017-18-LIMVORASAK-ONC	ONCPHARM2017-01: Improving safety and quality of cancer care in patients receiving checkpoint inhibitors for treatment of advance malignancies (I-CARE) (IRB#50345)
McAndrew, Philomena	A221405	A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE) (IRB# 45485).
McArthur, Heather	BIG16-05/AFT-27/WO39391	BIG 16-05/AFT-27/WO39391: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMPASSION030 AFT-27) (IRB#53409)
McArthur, Heather	IIT2018-04-MCARTHUR-NEOHP	IIT2018-04-MCARTHUR-NEOHP: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (IRB#53566)
McArthur, Heather	CO39611	CO39611: Phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with HR-positive, HER2-negative breast cancer (IRB# 50969)
McArthur, Heather	I3Y-MC-JPCF	I3Y-MC-JPCF: monarchE: Protocol I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (IRB#52637)
Mita, Monica	SGNLVA-001	A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer (IRB#33575)
Mita, Monica	MCLA-128-CL02	MCLA-128-CL02: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC (IRB#52060)
Mita, Monica	SO-BCA-003	SO-BCA-003: Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer (IRB #48750)
Mita, Monica	RGX-104-001	A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (IRB#46271)
Mita, Alain	XMAB20717-01	XmAb20717-01: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (IRB #53244)
Mita, Monica	IIT2018-25-MITA-NEOBREADS	IIT2018-25-MITA-NEOBREADS: Neoadjuvant Breast Diet Study (IRB#55782)
Mita, Monica	IIT2015-20-MITA-CSMCMATCH	Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute (IRB#44912)
Mita, Monica	IIT2015-18-MITA-MK3475	Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Advanced BRCA-mutated Breast Cancers (IRB#43955)
Mita, Alain	EAY131	EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419)
Mita, Monica	C0541001	C0541001: A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor (HER2) Positive Solid Tumors (IRB#51035)
Mita, Monica	BPT-201	BPT-201: A Phase 1/2, Multicenter, Single Arm, Open Label, Dose Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) in Patients with Relapsed or Refractory Solid Tumors (IRB#50135)
Mita, Monica	B9991025	B9991025: A PHASE 1b/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (IRB#53448)
Mita, Monica	A011106	ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study: (IRB#35572)
Natale, Ronald	IIT2017-11-NATALE-LUNG01	IIT2017-11-NATALE-LUNG01: Biomarkers of Targeted Therapy-Induced Apoptosis and Mechanisms of Sensitivity/Resistance in Patients with Advanced Cancers (IRB#53113)
Sankhala, Kamalesh	FPA150-001	FPA150-001: A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors (IRB#53268)
Shiao, Stephen	IIT2017-07-HO-PEMBRORT	IIT2017-07-HO-PEMBRORT: Pilot Study of the Preoperative Combination of Pembrolizumab and Radiation Therapy in Early Stage Breast Cancer of Any Subtype (IRB#49440)
Shiao, Stephen	IIT2015-07-SHIAO-HIFIDELI	Novel High Fidelity Functional Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis (IRB#43055)
Shiao, Stephen	IIT2016-18-SHIAO-NEOADSRS	IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027)

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.